Allogene Therapeutics to Participate in Citi’s Biopharma Summit in September 2025

SOUTH SAN FRANCISCO, Calif. — August 27, 2025 — Leads & Copy — Allogene Therapeutics, Inc. (Nasdaq: ALLO) will participate in Citi’s 2025 Biopharma Back to School Summit on Wednesday, September 3 at 7:30AM PT/10:30AM ET, according to a press release. Webcasts will be available on the company’s website.

Allogene Therapeutics, a clinical-stage biotechnology company, focuses on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease.

Christine Cassiano, EVP, Chief Corporate Affairs & Brand Strategy Officer, can be reached at Christine.Cassiano@allogene.com.

Source: Allogene Therapeutics

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.